两种方法治疗支气管哮喘疗效比较

Comparison of curative effect of two treatment methods in children with bronchial asthma

目的比较两种方法治疗支气管哮喘患儿的疗效。方法100例支气管哮喘患儿按住院单双号分成治疗组50例和对照组50例，治疗组每天吸入沙美特罗／氟替卡松粉吸入剂，每次50／100μg；对照组每天吸入丙酸氟替卡松吸入剂，每次100μg。所有病例分别于治疗后4、12周后，观察第一秒时间肺活量（FEV1）、呼气峰流速（PEF）、肺活量25％的瞬时流速（V75）、肺活量50％的瞬时流速（V50）、肺活量75％的瞬时流速（V25）及其占预计值的百分比。结果治疗4周后治疗组总有效43例（86．0％）高于对照组的28例（56．5％）（χ^2=3．987，P〈0．05）；治疗后12周两组患儿FEV1和PEF占预计值百分比较治疗前明显升高（χ^2=4．01、4．21、4．31、4．08，均P〈0．05），组间比较无统计学意义（χ^2=2．31、2．41，均P〉0．05）；两组治疗12周后V75、V50、V25分别达到了预计值的90％以上，两组治疗后V75、V50、V25与治疗前比较，改善明显（χ^2=4．285、4．234、4．311、4．278，均P〈0．05）。结论两种方法治疗支气管哮喘疗效肯定，沙美特罗／氟替卡松粉吸入剂治疗支气管哮喘疗效更佳。

Objective To investigate curative effect in children with bronchial asthma by two treatment methods：Methods 100 children with bronchial asthma,according to the different treatment were divided into treatment group 50 cases and control group （ 50 cases）. The first seconds vital capacity （ FEV1 ）, peak expiratory flow （PEF） ,vital capacity 25% of the instantaneous velocity （V75）, vital capacity 50% of the instantaneous velocity （V50） ,vital capacity 75% of the instantaneous velocity（ V25 ） and their percentage the percentage of predicted value were observed. Results Total effective of 43 cases（ 86.0% ） in treatment group after treatment 4 weeks were higher than that in control group of 28 cases （56.5%） （ χ^2 = 3.987, P 〈 0.05 ） ; The percentage of FEV1 and PEF in two groups after treatment 12 weeks were significantly higher than that before treatment（ χ^2 =4. 01,4.21,4. 31,4. 08,all P 〈0. 05）, but it between the two groups was not statistically significant （ χ^2 = 2. 31,2. 41, all P 〉 0. 05） ; The pulmonary function of V75 ,V50,V25 in two groups after treatment 12 weeks reached projected value of more than 90% ;The pulmonary function of V75 ,V50,V25 after treatment compared with those before treatment were improved significantly （χ^2 = 4. 285,4. 234,4. 311, 4. 278, all P 〈 0. 05 ）. Conclusion The curative effect of bronchial asthma were confirmed in two methods, but treatment group were better than the control group.